Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
QIFENG
873169
5
LAISAI LASER
871263
CN Stock MarketDetailed Quotes
688247 Sinotherapeutics Inc.
- 9.53
- -0.24-2.46%
Market Closed May 9 15:00 CST
4.32BMarket Cap34.53P/E (TTM)
9.82High9.50Low35.50KlotVolume9.69Open9.77Pre Close33.98MTurnover2.50%Turnover Ratio33.79P/E (Static)453.34MShares14.0052wk High3.34P/B1.36BFloat Cap7.3852wk Low11.72Limit Up142.32MShs Float27.87Historical High7.82Limit Down3.28%Amplitude6.23Historical Low0.07Dividend TTM9.57Avg Price23.62KlotAsk0.69%Div YieldTTM100Lot Size11.18KlotBid
Sinotherapeutics Inc. Key Stats
All
YOY
| (Q3)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ||||||||||
| Goods sale service render cash | 44.61%165.6M | 62.71%525.07M | 43.62%369.84M | 70.22%236.13M | 70.59%114.52M | 33.91%322.7M | 48.10%257.52M | 1.77%138.72M | 13.87%67.13M | -12.51%240.99M |
| Refunds of taxes and levies | -39.10%2.82M | 254.93%15.79M | 64.37%7.31M | 114.38%6M | 7,722.19%4.63M | -17.04%4.45M | 7.15%4.45M | 88,395.92%2.8M | --59.19K | -12.07%5.36M |
| Cash received relating to other operating activities | -85.90%839.37K | 39.70%16.44M | 69.83%14.03M | 33.63%7.43M | 264.41%5.95M | -28.30%11.77M | 8.95%8.26M | 230.27%5.56M | 71.64%1.63M | -79.39%16.41M |
| Cash inflows from operating activities | 35.30%169.26M | 64.44%557.3M | 44.76%391.19M | 69.68%249.56M | 81.77%125.1M | 28.98%338.91M | 45.58%270.23M | 6.58%147.08M | 14.89%68.82M | -27.24%262.76M |
| Goods services cash paid | -14.09%47.69M | 37.36%253.73M | 28.66%175.75M | 39.26%104.13M | 243.73%55.51M | 285.80%184.72M | 461.46%136.6M | 501.31%74.77M | 169.67%16.15M | -27.56%47.88M |
| Staff behalf paid | 38.81%32.73M | 18.56%88.02M | 17.74%64.55M | 16.41%43.39M | 24.89%23.58M | 5.39%74.24M | 6.01%54.83M | -4.88%37.28M | -17.15%18.88M | 2.43%70.44M |
| All taxes paid | 229.94%11.96M | 265.23%20.93M | 106.81%12.35M | 92.16%8.51M | -17.36%3.63M | -60.59%5.73M | -62.39%5.97M | -60.98%4.43M | -46.85%4.39M | 101.97%14.54M |
| Cash paid relating to other operating activities | -17.03%11.29M | 5.10%64.39M | 43.06%50.71M | 35.39%29M | 25.77%13.61M | 8.01%61.27M | -10.85%35.44M | -62.28%21.42M | -19.72%10.82M | -22.65%56.72M |
| Cash outflows from operating activities | 7.63%103.67M | 31.02%427.07M | 30.29%303.36M | 34.18%185.03M | 91.74%96.32M | 71.94%325.95M | 76.82%232.84M | 15.16%137.89M | -0.54%50.24M | -11.98%189.58M |
| Net cash flows from operating activities | 127.92%65.59M | 905.01%130.23M | 134.87%87.83M | 602.57%64.53M | 54.83%28.78M | -82.29%12.96M | -30.67%37.4M | -49.68%9.19M | 97.80%18.59M | -49.80%73.18M |
| Investing cash flow | ||||||||||
| Cash received from disposal of investments | 22.76%376.9M | -32.29%2.17B | -39.26%1.42B | -45.22%1.01B | -72.09%307.01M | 61.19%3.21B | 139.25%2.34B | 239.74%1.83B | 423.81%1.1B | 167.47%1.99B |
| Cash received from returns on investments | -32.95%1.06M | -30.47%10.98M | -24.12%7M | -30.99%5.09M | -30.94%1.57M | 129.55%15.79M | 153.92%9.23M | 216.98%7.37M | 206.78%2.28M | 57.21%6.88M |
| Cash inflows from investing activities | 22.48%377.96M | -32.28%2.18B | -39.20%1.43B | -45.16%1.01B | -72.00%308.59M | 61.42%3.22B | 139.30%2.35B | 239.64%1.84B | 423.04%1.1B | 166.83%2B |
| Cash paid to acquire fixed assets intangible assets and other long-term assets | 103.75%17.57M | 143.69%94.93M | 88.59%41.59M | 1.68%18.53M | 48.80%8.62M | -77.91%38.96M | -75.44%22.05M | -78.91%18.23M | -81.72%5.8M | 1,001.66%176.34M |
| Cash paid to acquire investments | -29.09%502.78M | -21.87%2.57B | -40.38%1.77B | -37.76%1.38B | -50.35%709M | 63.78%3.29B | 173.68%2.96B | 170.20%2.22B | 248.29%1.43B | 152.32%2.01B |
| Net cash paid to acquire subsidiaries and other business units | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --10.85M |
| Cash outflows from investing activities | -27.49%520.35M | -19.94%2.67B | -39.43%1.81B | -37.44%1.4B | -49.95%717.62M | 51.60%3.33B | 154.61%2.99B | 146.45%2.23B | 224.60%1.43B | 170.39%2.2B |
| Net cash flows from investing activities | 65.19%-142.39M | -349.78%-483.84M | 40.28%-377.57M | 1.13%-387.44M | -23.38%-409.04M | 46.30%-107.57M | -234.24%-632.22M | -7.63%-391.85M | -43.54%-331.52M | -211.84%-200.31M |
| Financing cash flow | ||||||||||
| Cash received from capital contributions | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --389.93M |
| Cash inflows from financing activities | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --389.93M |
| Dividend interest payment | ---- | -0.81%27.88M | -34.48%18.42M | --18.42M | ---- | --28.11M | --28.11M | ---- | ---- | ---- |
| Cash payments relating to other financing activities | -99.95%16.84K | 22,413.72%36.22M | 25,111.88%36.22M | 27,631.08%35.06M | 32,395.20%32.35M | -98.87%160.86K | -98.94%143.64K | -93.04%126.43K | -47.71%99.56K | 1,430.95%14.28M |
| Cash outflows from financing activities | -99.95%16.84K | 126.74%64.09M | 93.38%54.63M | 42,196.76%53.48M | 32,395.20%32.35M | 97.95%28.27M | 109.15%28.25M | -93.04%126.43K | -47.71%99.56K | 1,430.95%14.28M |
| Net cash flows from financing activities | 99.95%-16.84K | -126.74%-64.09M | -93.38%-54.63M | -42,196.76%-53.48M | -32,395.20%-32.35M | -107.53%-28.27M | -107.51%-28.25M | 93.04%-126.43K | 47.71%-99.56K | 40,373.03%375.65M |
| Net cash flow | ||||||||||
| Exchange rate change effecting cash and cash equivalents | -103.59%-9.01K | 12.50%1.71M | -87.13%223.67K | -8.90%1.6M | 177.21%251.23K | -48.87%1.52M | -54.37%1.74M | -33.51%1.76M | 6.18%-325.39K | 202.37%2.97M |
| Net increase in cash and cash equivalents | 81.37%-76.83M | -242.77%-416M | 44.61%-344.15M | 1.64%-374.78M | -31.60%-412.36M | -148.26%-121.36M | -353.58%-621.33M | -10.44%-381.03M | -41.09%-313.35M | 223.65%251.5M |
| Add:Begin period cash and cash equivalents | -64.82%225.79M | -15.90%641.78M | -15.90%641.78M | -15.90%641.78M | -15.90%641.78M | 49.15%763.15M | 49.15%763.15M | 49.15%763.15M | 49.15%763.15M | 17.91%511.65M |
| End period cash equivalent | -35.07%148.96M | -64.82%225.79M | 109.88%297.64M | -30.12%267.01M | -48.99%229.42M | -15.90%641.78M | -81.26%141.81M | 129.29%382.11M | 55.34%449.79M | 49.15%763.15M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- | -- | -- |
| Auditor | -- | Shanghui Certified Public Accountants (Special General Partnership) | -- | -- | -- | Shanghui Certified Public Accountants (Special General Partnership) | -- | -- | -- | Shanghui Certified Public Accountants (Special General Partnership) |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Market Insights
Discussing
Berkshire 2025 highlights: Stepping aside as CEO, trade and market volatility
$Berkshire Hathaway-A (BRK.A.US)$ held its highly anticipated annual shareholders meeting Saturday. Here are some key takeaways from the eve
Buffettttttt
May 3 21:00
Berkshire's 2025 Annual Shareholders Meeting